177 related articles for article (PubMed ID: 23473635)
21. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients.
Sun W; Sun Y; Zhu M; Wang Z; Zhang H; Xin Y; Jiang G; Guo X; Zhang Z; Liu Y
Oncol Rep; 2014 Mar; 31(3):1466-72. PubMed ID: 24378613
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
23. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
[TBL] [Abstract][Full Text] [Related]
24. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer.
Caramés C; Cristobal I; Moreno V; Marín JP; González-Alonso P; Torrejón B; Minguez P; Leon A; Martín JI; Hernández R; Pedregal M; Martín MJ; Cortés D; García-Olmo D; Fernández MJ; Rojo F; García-Foncillas J
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271609
[TBL] [Abstract][Full Text] [Related]
26. Mucinous Rectal Adenocarcinoma Is Associated with a Poor Response to Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis.
McCawley N; Clancy C; O'Neill BD; Deasy J; McNamara DA; Burke JP
Dis Colon Rectum; 2016 Dec; 59(12):1200-1208. PubMed ID: 27824706
[TBL] [Abstract][Full Text] [Related]
27. Complete pathological response in rectal cancer utilising novel treatment strategies for neo-adjuvant therapy: A systematic review.
Wilson K; Flood M; Narasimhan V; Pham T; Warrier S; Ramsay R; Michael M; Heriot A
Eur J Surg Oncol; 2021 Aug; 47(8):1862-1874. PubMed ID: 33814240
[TBL] [Abstract][Full Text] [Related]
28. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
Krajnović M; Marković B; Knežević-Ušaj S; Nikolić I; Stanojević M; Nikolić V; Šiljić M; Jovanović Ćupić S; Dimitrijević B
Pathol Res Pract; 2016 Jul; 212(7):598-603. PubMed ID: 27184911
[TBL] [Abstract][Full Text] [Related]
29. Delaying surgery after neoadjuvant chemoradiotherapy in rectal cancer has no influence in surgical approach or short-term clinical outcomes.
Figueiredo N; Panteleimonitis S; Popeskou S; Cunha JF; Qureshi T; Beets GL; Heald RJ; Parvaiz A
Eur J Surg Oncol; 2018 Apr; 44(4):484-489. PubMed ID: 29398323
[TBL] [Abstract][Full Text] [Related]
30. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
[TBL] [Abstract][Full Text] [Related]
31. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
[TBL] [Abstract][Full Text] [Related]
32. Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers.
Clarke TL; White DA; Osborne ME; Shaw AM; Smart NJ; Daniels IR
Ann R Coll Surg Engl; 2017 May; 99(5):373-377. PubMed ID: 28462648
[TBL] [Abstract][Full Text] [Related]
33. ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Yoon G; Park JY; Kim HJ; Choi GS; Kim JG; Kang BW; Kang MK; Seo AN
Anticancer Res; 2019 Jun; 39(6):2845-2853. PubMed ID: 31177122
[TBL] [Abstract][Full Text] [Related]
34. Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer.
Yoon G; Kim SM; Kim HJ; Seo AN
Tumour Biol; 2016 Mar; 37(3):3571-80. PubMed ID: 26456957
[TBL] [Abstract][Full Text] [Related]
35. Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer.
Yagishita S; Horinouchi H; Sunami KS; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T; Ohe Y
Cancer Sci; 2015 Oct; 106(10):1402-7. PubMed ID: 26177347
[TBL] [Abstract][Full Text] [Related]
36. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
[TBL] [Abstract][Full Text] [Related]
37. Complete response after neoadjuvant therapy in rectal cancer: to operate or not to operate?
Dedemadi G; Wexner SD
Dig Dis; 2012; 30 Suppl 2():109-17. PubMed ID: 23207942
[TBL] [Abstract][Full Text] [Related]
38. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.
Petrelli F; Sgroi G; Sarti E; Barni S
Ann Surg; 2016 Mar; 263(3):458-64. PubMed ID: 24263329
[TBL] [Abstract][Full Text] [Related]
39. Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis.
Shaikh I; Askari A; Ourû S; Warusavitarne J; Athanasiou T; Faiz O
Int J Colorectal Dis; 2015 Jan; 30(1):19-29. PubMed ID: 25367179
[TBL] [Abstract][Full Text] [Related]
40. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
